益生菌在治疗非酒精性脂肪性肝病中的研究进展

Research Progress of Probiotics in Treatment of Non-alcoholic Fatty Liver Disease

由于肥胖症的流行,非酒精性脂肪性肝病(NAFLD)成为一个全球性的健康问题,也是慢性肝损害的主要原因,而肠道菌群紊乱可能是NAFLD发病的原因之一。除肠道菌群紊乱导致肠道黏膜屏障损害、肠上皮通透性改变以及肠源性内毒素血症增加外,肠道细菌的代谢产物也发挥着重要作用。这使人们对益生菌补充剂作为NAFLD潜在的治疗方法产生了浓厚的兴趣,因为益生菌补充剂能够延缓甚至逆转肠道菌群失调,恢复正常的肠道菌群。益生菌在治疗NAFLD时耐受性和安全性均较好。以肠道菌群为靶点的益生菌疗法可能是未来治疗NAFLD的重要措施。

Due to the prevalence of obesity,non-alcoholic fatty liver disease(NAFLD)has become a global health problem and the main cause of chronic liver damage.The disturbance of intestinal flora may also be one of the causes of NAFLD.In addition to intestinal flora disorders resulted intestinal mucosal barrier damage,changes in intestinal epithelial permeability,and increased intestinal endotoxemia,intestinal bacterial metabolites also play an important role.This has led to a strong interest in probiotic supplements as a potential treatment for NAFLD,because probiotic supplements can delay or even reverse intestinal flora imbalance and restore normal intestinal flora.Current research shows that probiotics are well tolerated and safe in the treatment of NAFLD.Probiotic therapy targeting intestinal flora may be an important measure for the treatment of NAFLD in the future.